Alpelisib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NYE METODER (Norway) and TLV (Sweden) recommended or restricted alpelisib, while AOTMIT (Poland), CIPM (Spain) and DMC (Denmark), among others, did not recommend it.
The record spans 2.5 years, opening at AWMSG (Wales) on 10 Jun 2020 and running to 12 Dec 2022.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for alpelisib, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Against its own class, alpelisib is an outlier: 29% of its decisive outcomes were positive, where molecules sharing ATC class L01E average 75%.
3 distinct indication wordings are recorded for alpelisib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess alpelisib, on 10 Jun 2020; SMC (Scotland) did not open a file until 12 Dec 2022 — a moderate spread of 2.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 10 dated records fall in 2021 alone.
10 of the 18 agencies in this archive hold a record for alpelisib.
The full ledger for alpelisib reads 5 not recommended, 2 recommended, 1 terminated and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 12 Dec 2022 | In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-n… | not recommended | source |
| NICE (England) | 10 Aug 2022 | NICE TA816 | terminated appraisal | source |
| NYE METODER (Norway) | 22 May 2022 | Kombinasjonsbehandling med fulvestrant til postmenopausale kvinner, samt menn, med hormonreseptor (HR)-positiv, human ep… | introduced | source |
| DMC (Denmark) | 18 May 2022 | Lokalt fremskreden eller metastatisk ER+/HER2- brystkræft med PIK3CA-mutation | Ikke anbefalet | source |
| AOTMIT (Poland) | 3 Dec 2021 | programu lekowego B.9. „Leczenie chorych na raka piersi (ICD-10 C50) | not recommended | source |
5 further decisions for alpelisib, across 5 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 10 decisions for alpelisib from 10 agencies, 2020 to 2022. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.